Rigel Pharmaceuticals RIGL Product sales, net — Revenue recognized
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's product sales, net — revenue recognized.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's product sales, net — revenue recognized?
- Rigel Pharmaceuticals (RIGL) reported product sales, net — revenue recognized of $54.92M in Q1 2026.
- How has Rigel Pharmaceuticals's product sales, net — revenue recognized changed year-over-year?
- Rigel Pharmaceuticals's product sales, net — revenue recognized increased by 26.1% year-over-year, from $43.55M to $54.92M.
- What is the long-term trend for Rigel Pharmaceuticals's product sales, net — revenue recognized?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's product sales, net — revenue recognized has grown at a 38.5% compound annual growth rate (CAGR), from $63.01M to $231.98M.
- What does product sales, net — revenue recognized mean?
- This metric represents the total revenue generated from the direct sale of pharmaceutical products after accounting for variable considerations such as rebates, discounts, returns, and allowances. It serves as a primary indicator of commercial adoption and market demand for the company's proprietary therapeutic portfolio. Tracking this figure allows investors to evaluate the underlying growth trajectory and revenue-generating capacity of the company's core commercialized assets.